Nabitan

Nabitan

Nabitan

Synthetic cannabinoid

Nabitan (Nabutam, Benzopyranoperidine, SP-106, Abbott 40656) is a synthetic cannabinoid analog of dronabinol (Marinol) and dimethylheptylpyran.[1] It exhibits antiemetic and analgesic effects, most likely by binding to and activating the CB1 and CB2 cannabinoid receptors, and reduced intraocular pressure in animal tests, making it potentially useful in the treatment of glaucoma.[2]

Quick Facts Clinical data, ATC code ...

Nabitan has the advantage of being water-soluble, unlike most cannabinoid derivatives, and was researched for potential use as an analgesic or sedative,[3] although it was never developed for clinical use and is not currently used in medicine, as dronabinol or nabilone were felt to be more useful. However it is sometimes used in research into the potential therapeutic applications of cannabinoids.

See also

References

  1. [1]
    Razdan RK. The Total Synthesis of Cannabinoids. Wiley-Interscience 1980
  2. [2]
    Razdan RK, Howes JF (1983). "Drugs related to tetrahydrocannabinol". Medicinal Research Reviews. 3 (2): 119–46. doi:10.1002/med.2610030203. PMID 6134882. S2CID 31313909.
  3. [3]
    Archer RA (1974). "The cannabinoids: therapeutic potentials". Annual Reports in Medicinal Chemistry. 9: 253–9. doi:10.1016/s0065-7743(08)61448-7. PMID 12307093.
Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Nabitan, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.